As people around the world seek ways to manage their diabetes, the continuous glucose monitor (CGM) market continues to grow ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

Dublin, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The "Continuous Glucose Monitoring (CGM) Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. The Continuous ...

The use of CGM has been growing among people without diabetes, including those with prediabetes, particularly with the ...

Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.

A continuous glucose monitor is a better option than pricking your finger daily. These wearable devices are stuck to your arm and connect to an app on your smartphone or Apple Watch to easily test ...

The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...

Walmart will become the first U.S. retailer to sell Abbott’s continuous glucose monitoring device as the medtech giant looks to broaden its sales potential for its growing business unit. | Walmart ...

Please provide your email address to receive an email when new articles are posted on . McKee and colleagues conducted a retrospective survey of adults attending the Washington ...

“Let’s see what a Snickers bar does to my blood sugar,” Justin Richard, a 52-year-old Toronto-based TikToker says just before eating the candy bar on camera. After an edited time skip, Richard says, ...

Continuous glucose monitors (CGMs) may help curb the severity of hypoglycemia after weight-loss operations and even other gastrointestinal procedures, according to recent findings from a small study ...

In a multivariable logistic regression analysis, use of CGM devices was associated with lower odds of diabetic retinopathy (OR 0.52, 95% CI 0.32-0.84, P=0.008) and proliferative diabetic retinopathy ...